Pneumonia in pregnant women with COVID-19: is it a new thrombotic microangiopathy in obstetric practice?

Abstract

Thrombotic microangiopathies during pregnancy and puerperium are rare and, if undiagnosed, can be life-threating conditions for both the mother and the baby. The aim of this review article is to briefly describe clinical profile and highlight the clues for a correct diagnosis of pregnancy-related thrombotic microangiopathies. Of particular interest and important practical significance are the presented data on changes in the hemostatic system in patients with a new coronavirus infection COVID-19 through the prism of thrombotic microangiopathies.

Keywords

thrombotic microangiopathy / new coronavirus infection COVID-19 / thromboembolic events / hemostasis system

References

[1] Письмо Министерства здравоохранения РФ от 5 мая 2017 г. № 15-4/1560-07 «О направлении для использования в работе информационно-методического письма „Тромботическая микроангиопатия в акушерстве“» [Letter from the Ministry of health of the Russian Federation No. 15-4/1560-07 “O napravlenii dlya ispol’zovaniya v rabote informacionno-metodicheskogo pis’ma “Tromboticheskaya mikroangiopatiya v akusherstve””, dated 2017 May 5. (In Russ.)]. Доступно по: https://www.garant.ru/products/ipo/prime/doc/71627526/. Ссылка активна на 02.06.2020.

[2] Fakhouri F. Pregnancy-related thrombotic microangiopathies: Clues from complement biology. Transfus Apher Sci. 2016;54(2):199-202. https://doi.org/10.1016/j.transci.2016.04.009.

[3] Козловская Н.Л., Коротчаева Ю.В., Боброва Л.А., Шилов Е.М. Акушерский атипичный гемолитико-уремический синдром: первый российский опыт диагностики и лечения // Нефрология. – 2016. – Т. 20. – № 2. – С. 68–80. [Kozlovskaya NL, Korotchaeva YuV, Bobrova LA, Shilov EM. Obstetric atypical hemolytic uremic syndrome: the first russian experience of diagnosis and treatment. Nephrology. 2016;20(2):68-80. (In Russ.)]

[4] Sarno L, Stefanovic V, Maruotti G, et al. Thrombotic microangiopathies during pregnancy: The obstetrical and neonatal perspective. Eur J Obstet Gynecol Reprod Biol. 2019;237:7-12. https://doi.org/10.1016/j.ejogrb.2019. 03.018.

[5] George J, Nester C, McIntosh J. Syndromes of thrombotic microangiopathy associated with pregnancy. Hematology Am Soc Hematol Educ Program. 2015;2015(1):644-648. https://doi.org/10.1182/asheducation-2015.1.644.

[6] Vaught A, Braunstein E, Jasem J, et al. Germline mutations in the alternative pathway of complement predispose to HELLP syndrome. JCI Insight. 2018;3(6):e99128. https://doi.org/10.1172/jci.insight.99128.

[7] Laurence J, Haller H, Mannucci PM, et al. Atypical hemolytic uremic syndrome (aHUS): essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol. 2016;14 Suppl 11(11):2-15.

[8] Шилова Е.Р. Гематологические заболевания и синдромы, обусловленные нарушением регуляции системы комплемента. Современный взгляд на проблему. СПб., 2016. [Shilova ER. Gematologicheskie zabolevaniya i sindromy, obuslovlennye narusheniem regulyacii sistemy komplementa. Sovremennyy vzglyad na problemu. Saint Peterburg; 2016. (In Russ.)]. Доступно по: http://openhematology.ru/wp-content/uploads/2016/04/%D0%A8%D0%B8%D0%BB%D0%BE%D0%B2%D0%B0-%D0%95.%D0%A0.-%D0%93%D0%B5%D0%BC%D0%B0%D1%82%D0%BE%D0%BB%D0%BE%D0%B3%D0%B8%D1%87%D0%B5%D1%81%D0%BA%D0%B8%D0%B5-%D0%B7%D0%B0%D0%B1%D0%BE%D0%BB%D0%B5%D0%B2%D0%B0%D0%BD%D0%B8%D1%8F-%D0%B8-%D1%81%D0%B8%D0%BD%D0%B4%D1%80%D0%BE%D0%BC%D1%8B.pdf. Ссылка активна на 02.06.2020.

[9] Gupta M, Govindappagari S, Burwick RM. Pregnancy-Associated atypical hemolytic uremic syndrome: a systematic review. Obstet Gynecol. 2020;135(1):46-58. https://doi.org/10.1097/AOG.0000000000003554.

[10] Malinowski AK. Thrombotic microangiopathy in pregnancy: when you hear hoofbeats, consider the zebras? Br J Haematol. 2020. https://doi.org/10.1111/bjh.16694.

[11] Laurence J. Recognition and treatment of syndromes linked to dysregulation of the alternative complement pathway. Transfus Apher Sci. 2016;54(2):179-180. https://doi.org/10.1016/j.transci.2016.04.006.

[12] Pourrat O, Coudroy R, Pierre F. Differentiation between severe HELLP syndrome and thrombotic microangiopathy, thrombotic thrombocytopenic purpura and other imitators. Eur J Obstet Gynecol Reprod Biol. 2015;189:68-72. https://doi.org/10.1016/j.ejogrb.2015.03.017.

[13] Alrahmani L, Willrich MA. The complement alternative pathway and preeclampsia. Curr Hypertens Rep. 2018;20(5):40. https://doi.org/10.1007/s11906-018-0836-4.

[14] Распопин Ю.С., Колесниченко А.П., Синявская Н.В., и др. Многоликая тромботическая микроангиопатия ― «ожерелье смерти» осложнений беременности и родов // Клиническая нефрология. − 2017. − № 2. − С. 32–36. [Raspopin YuS, Kolesnichenko AP, Sinyavskaya NV, et al. Manyfaced thrombotic microangiopatia − “necklace of death” of complications of pregnancy and childbirth. Klinicheskaia nefrologiia. 2017;(2):32-36. (In Russ.)]

[15] Стрижаков А.Н., Тимохина Е.В., Игнатко И.В., и др. Тромботическая микроангиопатия как проявление тяжелой преэклампсии и HELLP-синдрома. Вопросы гинекологии, акушерства и перинатологии. − 2017. − Т. 16. − № 6. − С. 89–92. [Strizhakov AN, Timokhina EV, Ignatko IV, et al. Thrombotic microangiopathy as a manifestation of severe preeclampsia and hellp syndrome. Voprosy ginekologii, akusherstva i perinatologii. 2017;16(6):89-92. (In Russ.)]. https://doi.org/10.20953/1726-1678-2017-6-89-92.

[16] Кирсанова Т.В., Виноградова М.А., Федорова Т.А. Имитаторы тяжелой преэклампсии и HELLP-синдрома: различные виды тромботической микроангиопатии, ассоциированной с беременностью // Акушерство и гинекология. − 2016. − № 12. − С. 5–14. [Kirsanova TV, Vinogradova MA, Fedorova TA. The imitators of severe preeclampsia and HELLP syndrome: different types of pregnancy-associated thrombotic microangiopathy. Obstetrics and gynecology. 2016;(12):5-14. (In Russ.)]. https://doi.org/10.18565/aig.2016.12.5-14.

[17] Калачин К.А., Грищук К.И., Шмаков Р.Г., и др. «Нетипичный» HELLP-синдром или атипичный гемолитико-уремический синдром? // Акушерство и гинекология. − 2017. − № 1. − С. 94–102. [Kalachin KA, Grishchuk KI, Shmakov RG, et al. Atypical HELLP syndrome or atypical hemolytic uremic syndrome? Obstetrics and gynecology. 2017;(1):94-102. (In Russ.)]. https://doi.org/10.18565/aig.2017.1.94-102.

[18] Макацария А.Д., Акиншина С.В., Бицадзе В.О. Тяжелые акушерские осложнения как проявление тромботической микроангиопатии // Акушерство и гинекология. − 2017. − № 4. − С. 21–26. [Makatsaria AD, Bitsadze VO, Akinshina SV. Severe forms of preeclampsia as a manifestation of thrombotic microangiopathy. Obstetrics and gynecology. 2017;(4):21-26. (In Russ.)]. https://doi.org/10.18565/aig.2017.4.21-6.

[19] Рябоконь Н.Р., Кузнецова Л.В., Зазерская И.Е. Влияние преэклампсии на физиологические и патологические процессы в сосудах и риски развития сердечно-сосудистых заболеваний после родов // Трансляционная медицина. − 2014. − № 4. − С. 46–50. [Ryabokon NR, Kuznetsova LV, Zazerskaya IE. Influence of preeclampsia into physiological and pathological processes in the vessels and the risk of heart disease after birth. Translyatsionnaya meditsina. 2014;(4):46-50. (In Russ.)]

[20] Яковлева Н.Ю., Хазова Е.Л., Васильева Е.Ю., Зазерская И.Е. Соотношение ангиогенных и антиангиогенного факторов при преэклампсии // Артериальная гипертензия. − 2016. − Т. 22. − № 5. − С. 488–494. [Yakovleva NYu, Khazova EL, Vasil’eva EYu, Zazerskaya IE. Ratio of angiogenicand anti-angiogenic factors in preeclampsia. Arterial’naya gipertenziya. 2016;22(5):488-494. (In Russ.)]. https://doi.org/10.18705/1607-419X-2016-22-5-488-494.

[21] Прокопенко Е., Фомин А., Кошелев Р., и др. Трудности диагностики и лечения тромботической тромбоцитопенической пурпуры // Врач. − 2011. − № 5. − С. 25–29. [Prokopenko E, Fomin A, Koshelev R, et al. Difficulties in the diagnosis and treatment of thrombotic thrombocytopenic purpura. Vrach. 2011;(5):25-29. (In Russ.)]

[22] Arnold D, Patriquin C, Nazy I. Thrombotic microangiopathies: a general approach to diagnosis and management. Can Med Assoc J. 2016;189(4):E153-E159. https://doi.org/10.1503/cmaj.160142.

[23] Regal J, Gilbert J, Burwick R. The complement system and adverse pregnancy outcomes. Mol Immunol. 2015;67(1):56-70. https://doi.org/10.1016/j.molimm.2015.02.030.

[24] Bruel A, Kavanagh D, Noris M, et al. Hemolytic uremic syndrome in pregnancy and postpartum. Clin J Am Soc Nephrol. 2017;12(8):1237-1247. https://doi.org/10.2215/CJN.00280117.

[25] Padmanabhan A, Connelly‐Smith L, Aqui N, et al. Guidelines on the use of therapeutic apheresis in clinical practice — evidence‐based approach from the writing committee of the American Society for apheresis: The eighth special issue. J Clin Apher. 2019;34(3):171-354. https://doi.org/10.1002/jca.21705.

[26] Gruppo RA, Rother RP. Eculizumab for congenital atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):544-546. https://doi.org/10.1056/NEJMc0809959.

[27] Nürnberger J, Philipp T, Witzke O, et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med. 2009;360(5):542-544. https://doi.org/10.1056/NEJMc0808527.

[28] Worldometer [Internet]. COVID-19 coronavirus pandemic. Available from: https://www.worldometers.info/coronavirus/.

[29] Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395(10229):1054-1062. https://doi.org/10.1016/s0140-6736(20)30566-3.

[30] Liu J, Zheng X, Tong Q, et al. Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS‐CoV, MERS‐CoV, and 2019‐nCoV. J Med Virol. 2020;92(5):491-494. https://doi.org/10.1002/jmv.25709.

[31] Di Micco P, Russo V, Carannante N, et al. Clotting Factors in COVID-19: Epidemiological association and prognostic values in different clinical presentations in an Italian Cohort. J Clin Med. 2020;9(5):1371. https://doi.org/10.3390/jcm9051371.

[32] Clerkin KJ, Fried JA, Raikhelkar J, et al. Coronavirus disease 2019 (COVID-19) and cardiovascular disease. Circulation. 2020;141(20):1648-1655. https://doi.org/10.1161/CIRCULATIONAHA.120.046941.

[33] Klok F, Kruip M, van der Meer N, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. Thromb Res. 2020;191:148-150. https://doi.org/10.1016/ j.thromres.2020.04.041.

[34] Cui S, Chen S, Li X, et al. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost. 2020;18(6):1421-1424. https://doi.org/10.1111/jth.14830.

[35] Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. J Clin Virol. 2020;127:104362. https://doi.org/10.1016/j.jcv.2020.104362.

[36] Subramaniam S, Scharrer I. Procoagulant activity during viral infections. Front Biosci (Landmark Ed). 2018;23:1060-1081. https://doi.org/10.2741/4633.

[37] Van der Poll T, Levi M. Crosstalk between inflammation and coagulation: the lessons of sepsis. Curr Vasc Pharmacol. 2012;10(5):632-638. https://doi.org/10.2174/1570 16112801784549.

[38] Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-847. https://doi.org/10.1111/jth.14768.

[39] Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020;395(10223):507-513. https://doi.org/10.1016/s0140-6736(20)30211-7.

[40] Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel Coronavirus-Infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-1069. https://doi.org/10.1001/jama.2020.1585.

[41] Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: A multicenter prospective cohort study. Intensive Care Med. 2020;46(6):1089-1098. https://doi.org/10.1007/s00134-020-06062-x.

[42] Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb Res. 2020;191:9-14. https://doi.org/10.1016/ j.thromres.2020.04.024.

[43] Marini JJ, Gattinoni L. Management of COVID-19 respiratory distress. JAMA. 2020. https://doi.org/10.1001/jama.2020.6825.

[44] Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-1100. https://doi.org/10.1093/cvr/cvaa078.

[45] Wan Y, Shang J, Graham R, et al. Receptor recognition by the Novel Coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS Coronavirus. J Virol. 2020;94(7):e00127-20. https://doi.org/10.1128/JVI.00127-20.

[46] Zhang Y, Xiao M, Zhang S, et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med. 2020;382(17):e38. https://doi.org/10.1056/NEJMc2007575.

[47] Gavriilaki E, Brodsky RA. Severe COVID-19 infection and thrombotic microangiopathy: Success does not come easily. Br J Haematol. 2020;189(6):e227-e230. https://doi.org/10.1111/bjh.16783.

[48] Gralinski L, Sheahan T, Morrison T, et al. Complement activation contributes to severe acute respiratory syndrome Coronavirus pathogenesis. mBio. 2018;9(5):e01753-18. https://doi.org/10.1128/mBio.01753-18.

[49] Magro C, Mulvey JJ, Berlin D, et al. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl Res. 2020;220:1-13. https://doi.org/10.1016/j.trsl.2020.04.007.

[50] Diurno F, Numis FG, Porta G, et al. Eculizumab treatment in patients with COVID-19: Preliminary resultsfrom real life ASL Napoli 2 Nord experience. Eur Rev Med Pharmacol Sci. 2020;24(7):4040-4047. https://doi.org/10.26355/eurrev_202004_20875.

[51] Della Gatta AN, Rizzo R, Pilu G, Simonazzi G. Coronavirus disease 2019 during pregnancy: A systematic review of reported cases. Am J Obstet Gynecol. 2020;223(1):36-41. https://doi.org/10.1016/j.ajog.2020.04.013.

[52] Zimmermann P, Curtis N. COVID-19 in children, pregnancy and neonates: A review of epidemiologic and clinical features. Pediatr Infect Dis J. 2020;39(6):469-477. https://doi.org/10.1097/inf.0000000000002700.

[53] Linnemann B, Scholz U, Rott H, et al. Treatment of pregnancy-associated venous thromboembolism — position paper from the Working Group in Women’s Health of the Society of Thrombosis and Haemostasis (GTH). Vasa. 2016;45(2):103-118. https://doi.org/10.1024/0301-1526/a000504.

[54] Royal College of Obstetricians and Gynaecologists [Internet]. Thrombosis and Embolism during Pregnancy and the Puerperium, Reducing the Risk (Green-top Guideline No. 37a). 2015. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37a/.

[55] Royal College of Obstetricians and Gynaecologists [Internet]. Version 11: updated 24 July 2020. Guidance for healthcare professionals on coronavirus (COVID-19) infection in pregnancy, published by the RCOG, Royal College of Midwives, Royal College of Paediatrics and Child Health, Public Health England and Public Health Scotland. Available from: https://www.rcog.org.uk/en/guidelines-research-services/guidelines/coronavirus-pregnancy/.

[56] Временные методические рекомендации по профилактике, диагностике и лечению новой коронавирусной инфекции 2019-nCoV. Версия 6 от 28.04.2020 [Vremennyye metodicheskiye rekomendatsii po profilaktike, diagnostike i lecheniyu novoy koronavirusnoy infektsii 2019-nCoV. Version 6, 28.04.2020. (In Russ.)]. Доступно по: https://static-1.rosminzdrav.ru/system/attachments/attaches/000/050/122/original/28042020_%D0%9CR_COVID-19_v6.pdf. Ссылка доступна на 12.05.2020.

[57] Беженарь В.Ф., Айламазян Э.К., Зазерская И.Е., и др. Краткие клинические рекомендации. Тактика ведения беременных, рожениц и родильниц с подозрением или подтвержденной инфекцией COVID-19. МКБ-10: U07.2, U07.1. – СПб.: Эко-Вектор, 2020. – 47 с. [Bezhenar’ VF, Aylamazyan EK, Zazerskaya IE, et al. Kratkiye klinicheskiye rekomendatsii. Taktika vedeniya beremennykh, rozhenits i rodil’nits s podozreniyem ili podtverzhdennoy infektsiyey COVID-19. MKB-10: U07.2, U07.1. Saint Peterburg: Eko-Vektor; 2020. 47 р. (In Russ.)]. https://doi.org/https://doi.org/10.17816/JOWDS20201.

[58] Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association? Eur Heart J. 2020;41(19):1858. https://doi.org/10.1093/eurheartj/ehaa254.

[59] Povalyaev D. The efficacy of adjuvant use low molecular weight heparins in patients with community-acquired pneumonia. Eur Resp J. 2014;44(Suppl 58):2503.

RIGHTS & PERMISSIONS

Zazerskaya I.E., Bezhenar V.F., Godzoyeva A.O., Ishkarayeva V.V.